JAK1 and posterior cortical atrophy: To test whether the synergistic effects of JAK1 inhibitors and docetaxel in PCa cells could be mediated through inhibition of STAT3 and/or PI3K/AKT signalling, we treated the DU145 and PC3 cells with an IC50 concentration of docetaxel (10nM) in the presence or absence of the JAK1 inhibitors (ruxolitinib and baricitinib) followed by evaluating the effects of the combinations on STAT3 and AKT phosphorylation.